| abstract |
(57) [Summary] (Modified) [Object] To provide a pharmaceutical composition for use in preventing or treating ulcerative gastrointestinal disease, or preventing or treating inflammatory disease without causing gastrointestinal ulcer. A pharmaceutical composition comprising a thromboxane A 2 receptor antagonist alone or a combination of a thromboxane A 2 receptor antagonist and an anti-inflammatory agent. A specific example of the thromboxane A 2 receptor antagonist is [1 S- [1α, 2α (Z), 3α (1E, 3S *, 4R *), 4α]]-7- [3- (3-Hydroxy-4-phenyl-1-pentenyl) -7-oxabicyclo [2. 2.1] hept-2-yl] -5-heptenoic acid. |